Dystrogen Therapeutics

Dystrogen Therapeutics is developing a first-in-class chimeric cell therapy platform with broad applications in genetic and degenerative disorders. Its core technology involves fusing donor and recipient cells to create 'Dystrophin Expressing Chimeric (DEC)' cells that evade immune rejection, eliminating the need for immunosuppression. The company is initially focused on Duchenne Muscular Dystrophy, with a Phase 1 trial underway, and has preclinical programs targeting sarcopenia, age-related muscle loss, and neurodegenerative diseases. Dystrogen's approach represents a potentially paradigm-shifting alternative to gene therapy and other advanced modalities.

A chimeric cell engineering platform that fuses donor and recipient cells to create therapeutic cells that produce missing proteins (e.g., dystrophin) while evading immune rejection, eliminating the need for immunosuppression.

Total raised: $4M

Dystrogen competes with gene therapy leaders like Sarepta and Pfizer in DMD, as well as exon-skipping and stop-codon readthrough approaches. Its main differentiation is offering a universal, immunosuppression-free therapy that delivers full-length dystrophin without genetic manipulation or viral vectors, potentially offering a superior safety and efficacy profile.